Modern vaccine, Ema: “Hypothesis more risk for heart after second dose”

More risk of heart side effects after second dose of Moderna vaccine. “Preliminary analyzes” of new data, relating to reports of undesirable cardiac effects following vaccination against Covid with mRna products, and “from Nordic countries” including Sweden and Denmark, “indicate the possibility that the risk of myocarditis in younger men may be greater after a second dose of Spikevax “, Moderna’s vaccine,” compared to a second dose of Pfizer – BioNTech’s Comirnaty, “although further evaluation is required,” Ema told Adnkronos. Health. Read also “The Prac will evaluate the new data to determine if it is necessary to update the current recommendations in the product information”, after Sweden and Denmark announced the precautionary suspension of the administration of the Spikevax vaccine, respectively in the under 30 and under 18 populations In fact, “reports of side effects such as myocarditis and pericarditis are increasing”, explained the Swedish Public Health Agency, while specifying that “the risk of being affected by these side effects is very low”. “In July 2021 – recall from the European Medicines Agency – the PRAC concluded that myocarditis and pericarditis, inflammatory heart conditions, can occur in very rare cases after vaccination with Comirnaty or Spikevax, more often after the second dose and in younger men ” . For this “the committee recommended listing both conditions as side effects in the product information for these vaccines, along with a warning to raise awareness among health professionals and people receiving these vaccines. Health care professionals also received a notice” in Now, the EU regulatory body continues, “the Prac’s conclusions are supported by new analyzes of data from Nordic countries (Denmark, Finland, Norway and Sweden), which show myocarditis occurs more frequently after the second dose of Comirnaty and Spikevax “. But “preliminary analyzes” also suggest “the possibility that the risk of myocarditis in younger men may be higher after a second dose of Spikevax than after a second dose of Comirnaty, although further evaluation of the data is needed.” As previously communicated – again to recommend the EMA – health professionals must pay attention to the signs and symptoms of myocarditis and pericarditis in people vaccinated with Comirnaty or Spikevax “. In any case, the agency reiterates that” Covid vaccines- 19 authorized are effective in reducing the risk of Covid-19 “, as well as” hospital admissions and deaths due to Covid-19. As with all vaccines, the EMA will continue to evaluate the emerging data on these products, to ensure that the their benefits continue to outweigh their risks. “